OPEN-LABEL, UNCONTROLLED, CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AUTOLOGOUS FIBRIN-CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED FOR RESTORATION OF EPIDERMIS IN PATIENTS WITH JUNCTIONAL EPIDERMOLYSIS BULLOSA
Latest Information Update: 11 Apr 2023
At a glance
- Drugs LAMB3 encoding stem cell therapy (Primary)
- Indications Epidermolysis bullosa
- Focus Adverse reactions
- Acronyms Hologene 5
- Sponsors Holostem Terapie Avanzate
Most Recent Events
- 11 Apr 2023 Status changed from not stated to recruiting.
- 03 Apr 2023 New trial record